Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best multibagger stocks to invest in according to billionaires. On February 17, Cogent Biosciences released the earnings report for 2025 and entered 2026 with significant regulatory momentum following three positive pivotal trials for its lead candidate, bezuclastinib. The company submitted an NDA for Non-Advanced Systemic Mastocytosis/NonAdvSM in December 2025 and is on track to submit an additional NDA for Advanced Systemic Mastocytosis/AdvSM in H1 2026.

Furthermore, Cogent has initiated a rolling NDA for second-line gastrointestinal stromal tumors/GIST under the FDA’s Real-Time Oncology Review program, with completion expected by April this year. The clinical data supporting these filings remains robust, highlighted by the PEAK trial’s results in GIST patients, which showed a median progression-free survival of 16.5 months, nearly double that of the control group. In the SUMMIT trial for NonAdvSM, patients experienced significant symptomatic relief that continued to deepen over 48 weeks.

Beyond its lead program, Cogent is advancing a diverse pipeline of selective inhibitors, including CGT1145 for JAK2-driven diseases and CGT1815 for KRAS-mutant cancers, with multiple IND applications planned for the coming year. Cogent Biosciences Inc. (NASDAQ:COGT) ended 2025 with $900.8 million in cash and marketable securities. This capital, supported by a $546.8 million public offering in late 2025, is projected to fund operations into 2028.

Cogent Biosciences Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company that develops precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib, a selective tyrosine kinase inhibitor to target mutations within the KIT receptor tyrosine kinase.

While we acknowledge the potential of COGT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.